FOR SALE: Pharmaceutical Plant Liquidation

Published: 15-Feb-2021
Manufacturing Hi Tech Manufacturing Estates & Facilities Pharmaceutical

Register here to be kept inform of all update concerning the AVARA Project - complete contents of modern 100 acre pharmaceutical facility - API and intermediate large scale manufacturing equipment (assets formerly owned by Astra Zeneca/Avara). The auction ends on 28 February.

Assets formerly owned by ASTRAZENECA / AVARA

Complete Contents of Modern 100 Acre Large Scale API Production & Development Facility Nearby Bristol, UK

Site Capabilities

Five Large-Scale cGMP API PLANTS

  • Large volume commercial manufacture of intermediates & APIs
  • 6m3 to 10m3 reactor capacity
  • Pressure filter, conical and centrifuge drying
  • High hazard chemistry
  • Synthesis
  • Purification
  • Storage

Two Large-Scale Milling Facilities

  • Two Hosakawa mills, 315 UPZ and associated equipment
  • Matcon bin charging

CGMP Large-Scale Laboratory

  • 10 L to 100 L reactor capacity
  • Chlorination with POCl3
  • Oxidation with peroxide and hypochlorite
  • Grignard reagents
  • Metal catalysts
  • Formulation
  • Cryogenic reactions

For more information, REGISTER HERE

  • Companies:
  • Maynards
See more

You may also like

Manufacturing

Maynards to manage asset dispersal at former Avonmouth pharma site

Read more
Recently the company completed the dispersal of the complete contents of Recipharm’s Ashton-under-Lyne pharmaceutical manufacturing facility

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  2. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Maynards to manage asset dispersal at former Avonmouth pharma site

Recently the company completed the dispersal of the complete contents of Recipharm’s Ashton-under-Lyne pharmaceutical manufacturing facility
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

How CDMOs can set a new gold standard when it comes to going green

Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
Manufacturing

ACG expands global footprint with new capsule manufacturing facility in Thailand

New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Manufacturing

Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary

The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Manufacturing

£20m Scottish oligonucleotide manufacturing innovation centre now under construction

The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence
Subscribe now